← All trials
NCT04746131
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Apr 11, 2024
- Completion date
- Apr 11, 2024
- First posted
- Feb 9, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead sponsor
- Worldwide Clinical TrialsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.